Serum Institute gets DCGI notice over Oxford COVID-19 vaccine trial suspension by AstraZeneca abroad

The Drugs Controller General of India, Dr V G Somani, in his show-cause notice has asked SII as to why the permission granted for conducting phase 2 and 3 clinical trials of the vaccine candidate in the country be not suspended till patient safety is established.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news